A derivative of the Botulinum Toxin Type A called Abobotulinum Toxin A, Dysport was first approved by the FDA in 2009 as a treatment for deep wrinkles and lines. Some physicians have reported faster results with Dysport than with comparable Botox dosages. Additionally, patients who are no longer experiencing the expected results from Botox injections may be able to achieve effective smoothing of wrinkles by switching to Dysport. The side effects possible with Dysport injections are similar to those of Botox.